BRCTF Stock - BioArctic AB (publ)
Unlock GoAI Insights for BRCTF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $257.35M | $616.00M | $228.29M | $23.15M | $62.35M |
| Gross Profit | $230.37M | $526.37M | $153.97M | $-31,921,000 | $12.11M |
| Gross Margin | 89.5% | 85.5% | 67.4% | -137.9% | 19.4% |
| Operating Income | $-228,514,000 | $252.64M | $-17,442,000 | $-139,723,000 | $-85,012,000 |
| Net Income | $-177,079,000 | $229.25M | $-11,179,000 | $-119,789,000 | $-68,517,000 |
| Net Margin | -68.8% | 37.2% | -4.9% | -517.5% | -109.9% |
| EPS | $-2.00 | $2.59 | $-0.13 | $-1.36 | $-0.78 |
BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.
Visit WebsiteEarnings History & Surprises
BRCTFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 13, 2025 | $-0.12 | $-0.10 | +14.4% | ✓ BEAT |
Q2 2025 | Jun 30, 2025 | $0.16 | $0.11 | -29.6% | ✗ MISS |
Q1 2025 | Mar 31, 2025 | $1.03 | $1.15 | +11.7% | ✓ BEAT |
Q4 2024 | Dec 31, 2024 | $-0.06 | $-0.03 | +43.9% | ✓ BEAT |
Q3 2024 | Sep 30, 2024 | $-0.06 | $-0.02 | +64.7% | ✓ BEAT |
Q2 2024 | Jun 30, 2024 | $-0.07 | $-0.07 | -2.7% | ✗ MISS |
Q1 2024 | Mar 31, 2024 | $-0.08 | $-0.06 | +23.0% | ✓ BEAT |
Q4 2023 | Dec 30, 2023 | $-0.08 | $-0.10 | -25.3% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | $0.02 | $0.13 | +601.8% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $-0.09 | $-0.11 | -18.2% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | — | $0.32 | — | — |
Q1 2023 | Feb 3, 2023 | — | $-0.06 | — | — |
Q3 2022 | Sep 30, 2022 | — | $0.14 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.05 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.05 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.02 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.05 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.04 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.04 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.02 | — | — |
Frequently Asked Questions about BRCTF
What is BRCTF's current stock price?
What is the analyst price target for BRCTF?
What sector is BioArctic AB (publ) in?
What is BRCTF's market cap?
Does BRCTF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BRCTF for comparison